Bordetella Pertussis, Whooping Cough
7
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
12 treatments under study, led by Blood Sampling
Research Leaders
20 sponsors active, led by Institut Pasteur
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (7)
CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools
Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
Pertussis Challenge Study in Adults Vaccinated With BPZE1
Impact of Bacterial Expression and Immune Response in the Severity of Pertussis
Pertussis Immunization Programs in Low Income Countries
Pertussis Immunization Programs in Low Income Countries - Ivory Coast
EUpertstrain 4 Study of Bordetella Pertussis Isolates
Research Network
Common Treatments
- Blood Sampling2
- Nasopharyngeal Sampling2
- Bpze1 Pertussis Vaccine And Placebo1
- Strain Isolation From The Nasopharynx1
- Bordetella Pertussis Challenge Strain1
Active Sponsors
- Institut Pasteur3
- ILiAD Biotechnologies2
- Sanofi Pasteur, a Sanofi Company2
- Hôpital Armand Trousseau1
- Hôpital Louis Mourier1
Top Investigators
Institut Pasteur
Institut Pasteur
Institut Pasteur
Institut Pasteur of Cote d'Ivoire
The Hospital for Sick Children
Related Conditions
- Rsv Infection1
- Sars Cov 2 Infection1
- Pertussiswhooping Cough1
- Mycoplasma Pneumoniae1
- Influenza1